首页 | 本学科首页   官方微博 | 高级检索  
检索        

奥美沙坦酯片治疗轻中度原发性高血压的疗效和安全性
引用本文:荆珊,孙宁玲,柯元南,杨新春,何汝敏,吴宗贵,严晓伟,姚晨.奥美沙坦酯片治疗轻中度原发性高血压的疗效和安全性[J].中国临床药理学杂志,2006,22(1):3-6.
作者姓名:荆珊  孙宁玲  柯元南  杨新春  何汝敏  吴宗贵  严晓伟  姚晨
作者单位:1. 北京大学,人民医院,心内科,北京,100044
2. 中日友好医院,北京,100029
3. 北京朝阳医院,北京,100020
4. 上海瑞金医院,上海,200025
5. 上海长征医院,上海,200003
6. 北京协和医院,北京,100730
7. 北京大学,第一医院,北京,100034
摘    要:目的评价国产奥美沙坦酯片治疗轻中度原发性高血压的疗效和安全性。方法用随机双盲双模拟多中心活性药对照的试验设计,符合入选条件的221例轻中度原发性高血压患者随机分为奥美沙坦酯组和氯沙坦组,治疗8周,观察2组治疗前后的血压、心率、心电图和血尿实验室检查的变化。动态血压用开放试验方法,分别在安慰剂末期和治疗期结束时(未停药),做24h动态血压监测。结果奥美沙坦组与氯沙坦组比较,平均坐位收缩压和舒张压降低程度都有显著性差异,分别为17.22vs11.02mmHg,(P<0.01);13.41vs11.18mmHg(P<0.05)。奥美沙坦组降压总有效率为82.41%;每日1次服用奥美沙坦酯片作用可持续24h,药物降低收缩压和舒张压的谷峰比值均>50%。2组药物不良反应发生率分别为3.5%,5.4%,2组比较无显著性差别。结论国产奥美沙坦酯片治疗轻中度原发性高血压患者,能24h平稳降压,谷峰比满意,且耐受性较好。

关 键 词:奥美沙坦酯片  原发性高血压  动态血压
文章编号:1001-6821(2006)01-0003-04
收稿时间:2005-09-07
修稿时间:2005-11-28

Effects and safety of mild and moderate primary hypertension treated with olmesartan medoxomil tablet
JING Shan,SUN Ning-ling,KE Yuan-nan,YANG Xin-chun,HE Ru-min,WU Zong-gui,YAN Xiao-wei,YAO Chen.Effects and safety of mild and moderate primary hypertension treated with olmesartan medoxomil tablet[J].The Chinese Journal of Clinical Pharmacology,2006,22(1):3-6.
Authors:JING Shan  SUN Ning-ling  KE Yuan-nan  YANG Xin-chun  HE Ru-min  WU Zong-gui  YAN Xiao-wei  YAO Chen
Institution:1. Department of Cardiology, People Hospital, Peking University, Beijing 100044, China; 2. Sino - Japan Friendship Hospital, Beijing 100029, China; 3. Beijing Chaoyang Hospital, Beijing 100020, China ; 4. Shanghai Ruijin Hospital, Shanghai 200025, China; 5. Shanghai Changzheng Hospital, Shanghai 200003, China; 6. Peking Union Medical College Hospital, Belting 100073, China ; 7. The First Hospital, Peking University, Beijing 100034, China
Abstract:Objective To evaluate the effect and safety of olmesartan medoxomil in the treatment of patients with mild to moderate primary hypertension. Methods A randomized, double-blind, double-mimic controlled trial was performed. Two hundreds twenty-one patients with mild to moderate primary hypertension were randomly into olmesartan group and losartan group. The changes of blood pressure, heart rate, electrocardiogram , blood and urinary laboratory examination were observed. Open method was used in the clinical trial of ambulatory blood pressure. The 24-hour ambulatory blood pressure monitoring was investigated at the end of placebo and treatment period. Results ITT analysis, reduction in both systolic and diastolic blood pressure has significantly difference between two groups. In olmesartan and losartan group, the reduction of systolic blood pressure was 17.22 mmHg and 11.02 mmHg, separately. The reduction of diastolic blood pressure was 13.41 mmHg and 11.18 mmHg, separately. Normotension was achieved in 82.41% in olmesartan group. The antihypertensive effect of olmesartan can cover over 24 hours. The trough to peak ratios for systolic and diastolic blood pressure by olmesartan were all more than 50%. Adverse reactions were observed in 3.57%,5.4% of patients in the two groups(P>0.05). Conclusion The effect of olmesartan once daily can maintain for 24 hours. The trough to peak ratio is satisfied. Olmesartan is safe and effective for the treatment of mild to moderate hypertension.
Keywords:olmesartan medoxomil tablet  primary hypertension  ambulatory blood pressure monitoring  
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号